The eBook copy of this book is not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.
Everything pharmacists need to know about managing drug information for better patient outcomesDrug Information: A Guide for Pharmacists, 4eteaches pharmacists how to more effectively and efficiently research, interpret, collate and disseminate drug information in the most usable form possible.The book discusses how to determine what information is needed and how to respond adequately to requests for information. It also covers the ethical and legal aspects of drug information management.Features NEWcoverage of patient safety, project design and organizational problem solving NEWkey points added to each chapter NEWcase studies added to add real world relevance NEWstudy questions integrated throughout the chapters
Table of Contents
Chapter One. Introduction to the Concept of Medication Information Mary Lea Gora-Harper and J. Russell May Chapter Two. Formulating Effective Responses and Recommendations: A Structured Approach Karim Anton Calis and Amy Heck Sheehan Chapter Three. Drug Information Resources Kelly M. Shields and Elaine Blythe Chapter Four. Literature Evaluation I: Controlled Clinical Trial Evaluation Michael Kendrach, Maisha Kelly Freeman, Terri M. Wensel, and Peter J. Hughes Chapter Five. Literature Evaluation II: Beyond the Basics Patrick J. Bryant, Karen P. Norris, Cydney E. McQueen, and Elizabeth A. Poole Chapter Six. Pharmacoeconomics James P. Wilson and Karen L. Rascati Chapter Seven. Evidence-Based Clinical Practice Guidelines Kevin G. Moores Chapter Eight. The Application of Statistical Analysis in the Biomedical Sciences Ryan W. Walters and Karen L. Kier Chapter Nine. Professional Writing Patrick M. Malone Chapter Ten. Legal Aspects of Drug Information Practice Martha M. Rumore Chapter Eleven. Ethical Aspects of Drug Information Practice Linda K. Ohri Chapter Twelve. Pharmacy and Therapeutics Committee Patrick M. Malone, Nancy L. Fagan, Mark A. Malesker, and Paul J. Nelson Chapter Thirteen. Drug Evaluation Monographs Patrick M. Malone, Nancy L. Fagan, Mark A. Malesker, Paul J. Nelson, and Linda K. Ohri Chapter Fourteen. Quality Improvement and the Medication Use Process Mark A. Ninno and Sharon Davis Ninno Chapter Fifteen. Medication Misadventures I: Adverse Drug Reactions Philip J. Gregory and Zara Risoldi Cochrane Chapter Sixteen. Medication Misadventures II: Medication and Patient Safety Kathryn A. Crea Chapter Seventeen. Investigational Drugs Bambi Grilley Chapter Eighteen. Policy Development, Project Design, and Implementation Stacie Krick Evans Chapter Nineteen. Drug Information in Ambulatory Care Debra L. Parker Chapter Twenty. Drug Information and Contemporary Community Pharmacy Practice Morgan L. Sperry and Patricia A. Marken Chapter Twenty-One. Drug Information Education and Training Kelly M. Smith Chapter Twenty-Two. Pharmaceutical Industry and Regulatory Affairs: Opportunities for Drug Information Specialists Jean E. Cunningham and Lindsay E. Davison Appendix 2-1. Drug Consultation Request Form Appendix 2-2. Sample Questions for Obtaining Background Information From Requestors Appendix 3-1. Performing a PubMed Search Appendix 3-2. Selected Primary Literatures Sources Appendix 4-1. Questions for Assessing Clinical Trials Appendix 5-1. Beyond the Basics: Questions to Consider for Critique of Primary Literature Appendix 7-1. New Zealand Guidelines Group (NZGG) Appendix 7-2. National Institute for Clinical Excellence (NICE) Appendix 7-3. National Institute for Clinical Excellence (NICE) Topic Selection Criteria Appendix 7-4. Study Selection Process—Centre for Reviews and Dissemination (CRD) Appendix 7-5. Study Selection Points—Centre for Reviews and Dissemination (CRD) Appendix 7-6. Data Synthesis—Centre for Reviews and Dissemination (CRD)Appendix 7-7. National Institute for Clinical Excellence (NICE)—Evidence Table Format for Intervention Studies Appendix 7-8. New Zealand Guidelines Group (NZGG)—Considered Judgment Appendix 7-9. Guidelines Advisory Committee (GAC) —Levels of Evidence Grades of Recommendation Appendix 7-10. National Institute for Clinical Excellence (NICE) Guideline Structure Appendix 7-11. Scottish Intercollegiate Guidelines Network (SIGN) Consultation and Peer-Review Appendix 7-12. Grades of Recommendation Assessment Development and Evaluation (GRADE) System Advantages Appendix 7-13. Appraisal of Guidelines Research & Evaluation (AGREE) Instrument Appendix 7-14. Conference on Guideline Standardization (COGS) Checklist Appendix 7-15. Implementation Strategies Appendix 9-1. Question Example Appendix 9-2. Abstracts Appendix 9-3. Bibliography Appendix 11-1. Code of Ethics for Pharmacists Appendix 12-1. Pharmacy and Therapeutics Committee Procedure Appendix 12-2. Formulary Request Form Appendix 12-3. P&T Committee Meeting Attributes Appendix 12-4. Example P&T Committee Minutes Appendix 12-5. Chairperson Skills Appendix 12-6. Conflict-of-Interest Declaration Appendix 13-1. Format for Drug Monograph Appendix 13-2. Example Drug Monograph Appendix 14-1. Comparison of Quality Assurance and Total Quality Management in Health Care Appendix 14-2. Tools Used in Quality Improvement Appendix 14-3. Examples of Approaches to Quality Improvement Appendix 14-4. Example of a Quality Improvement Activity Plan Appendix 14-5. Example Report—Prescriber-Specific Results Appendix 14-6. Example of MUE Results Appendix 14-7. Quality Evaluation: Response to Drug Information Request Appendix 15-1. Kramer Questionnaire Appendix 15-2. Naranjo Algorithm Appendix 15-3. Jones Algorithm Appendix 15-4. MedWatch Form Appendix 17-1. Investigational New Drug Application Appendix 17-2. Statement of Investigator Appendix 17-3. Protocol Medication Economic Analysis Appendix 17-4. Investigational Drug Accountability Record Appendix 18-1. High-Alert Medications Appendix 18-2. Medication Shortages and Backorders Appendix 19-1. FDA Guidelines for Proper Medication Disposal Appendix 22-1. Response Letter: Drug A—Incidence of Yellow Stripes Glossary Answers for Case Studies Answers for Self-Assessment Questions Index